TGTX
HEALTHCARETG Therapeutics Inc
$41.97+5.87 (+16.26%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TGTX Today?
No stock-specific AI insight has been generated for TGTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$25.28$44.00
$41.97
Fundamentals
Market Cap$6.4B
P/E Ratio15.2
EPS$2.77
Dividend Yield—
Dividend / Share—
ROE1.0%
Profit Margin0.7%
Debt / Equity—
Trading
Volume6.6M
Avg Volume (10D)—
Shares Outstanding153.1M
TGTX News
21 articles- TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The TestSimply Wall Street·May 7, 2026
- TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewYahoo Finance·May 7, 2026
- Dow Jones Futures Rise, Oil Prices Fall On Iran-Deal Hopes, Nvidia Leads New Buys; ARM Is Earnings MoverYahoo Finance·May 7, 2026
- TG Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- TG Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- TG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- TG Therapeutics (TGTX) Q1 Earnings Lag EstimatesYahoo Finance·May 6, 2026
- TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceYahoo Finance·May 6, 2026
- TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateYahoo Finance·Apr 30, 2026
- Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance·Apr 28, 2026
- TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings GrowthYahoo Finance·Apr 27, 2026
- TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingYahoo Finance·Apr 22, 2026
- A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumYahoo Finance·Apr 19, 2026
- TGTX Completes Enrollment in Phase III Study on Subcutaneous BriumviYahoo Finance·Apr 16, 2026
- TG Therapeutics concludes enrolment in Phase III Briumvi trialClinicaltrialsarena·Apr 16, 2026
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIYahoo Finance·Apr 15, 2026
- Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?Yahoo Finance·Apr 3, 2026
- A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit FacilityYahoo Finance·Mar 24, 2026
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 MillionYahoo Finance·Mar 19, 2026
- What to Know About This Obesity Drug Developer That Just Drew a New $7 Million InvestmentMotley Fool·Mar 16, 2026
- This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock DropMotley Fool·Mar 16, 2026
All 21 articles loaded
Price Data
Open$36.25
Previous Close$36.10
Day High$41.24
Day Low$36.25
52 Week High$44.00
52 Week Low$25.28
52-Week Range
$25.28$44.00
$41.97
Fundamentals
Market Cap$6.4B
P/E Ratio15.2
EPS$2.77
Dividend Yield—
Dividend / Share—
ROE1.0%
Profit Margin0.7%
Debt / Equity—
Trading
Volume6.6M
Avg Volume (10D)—
Shares Outstanding153.1M
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—